Novo Nordisk announced on Monday that, starting immediately, it is offering a two-month introductory price of $199 a month for U.S.-based cash buyers of its top-selling diabetes and weight loss drugs — Ozempic and Wegovy. It's also lowering the "standard" price for existing cash buyers to $349 a month from $499.
